Alvelestat

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameAlvelestat
Drug Alias Name阿来司他Alvelestatum阿维司他MPH-966AZD-9668
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeukocyte elastase inhibitors
TargetsLeukocyte elastase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)EmphysemaGraft vs Host Disease +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[22] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesMereo BiopharmaMereo Biopharma Group PlcNational Cancer Institute +[4] 
Inactive CompaniesAstrazeneca PlcKafrelsheikh University
Active IndicationsCoronavirus Disease 2019 (COVID-19)EmphysemaGraft vs Host Disease +[6] 
Inactive IndicationsInsulin ResistanceDiabetes Mellitus, Type 2Bronchiectasis +[4] 

Other Information

ATC CodeN/A
Related LinksN/A